IL323210A - שילובים ושיטות לשיפור טיפולים במעכבי נקודות ביקורת בטיפול בסרטן - Google Patents

שילובים ושיטות לשיפור טיפולים במעכבי נקודות ביקורת בטיפול בסרטן

Info

Publication number
IL323210A
IL323210A IL323210A IL32321025A IL323210A IL 323210 A IL323210 A IL 323210A IL 323210 A IL323210 A IL 323210A IL 32321025 A IL32321025 A IL 32321025A IL 323210 A IL323210 A IL 323210A
Authority
IL
Israel
Prior art keywords
compound
formula
linker
pharmaceutically acceptable
subject
Prior art date
Application number
IL323210A
Other languages
English (en)
Inventor
John Victor Napoleon
Philip S Low
Madduri Srinivasarao
Original Assignee
Purdue Research Foundation
John Victor Napoleon
Philip S Low
Madduri Srinivasarao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, John Victor Napoleon, Philip S Low, Madduri Srinivasarao filed Critical Purdue Research Foundation
Publication of IL323210A publication Critical patent/IL323210A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
IL323210A 2023-03-23 2025-09-07 שילובים ושיטות לשיפור טיפולים במעכבי נקודות ביקורת בטיפול בסרטן IL323210A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363454306P 2023-03-23 2023-03-23
PCT/US2024/021385 WO2024197318A2 (en) 2023-03-23 2024-03-25 Combinations and methods for enhancing checkpoint inhibitor therapies in cancer treatment

Publications (1)

Publication Number Publication Date
IL323210A true IL323210A (he) 2025-11-01

Family

ID=92842550

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323210A IL323210A (he) 2023-03-23 2025-09-07 שילובים ושיטות לשיפור טיפולים במעכבי נקודות ביקורת בטיפול בסרטן

Country Status (6)

Country Link
EP (1) EP4683669A2 (he)
KR (1) KR20250170072A (he)
CN (1) CN121175070A (he)
AU (1) AU2024238457A1 (he)
IL (1) IL323210A (he)
WO (1) WO2024197318A2 (he)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3730152A4 (en) * 2017-12-21 2022-01-12 Sumitomo Dainippon Pharma Co., Ltd. COMBINATION DRUGS WITH TLR7 AGONIST
EP4178574A4 (en) * 2020-07-08 2024-04-10 Purdue Research Foundation Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer
CA3203439A1 (en) * 2021-01-04 2022-07-07 Philip S. Low Methods for enhancement of engineered cell therapies in cancer treatment
WO2022226032A1 (en) * 2021-04-21 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Immunostimulatory toll-like receptor agonist-nanoparticle for cancer immunotherapy

Also Published As

Publication number Publication date
EP4683669A2 (en) 2026-01-28
KR20250170072A (ko) 2025-12-04
AU2024238457A1 (en) 2025-10-16
WO2024197318A3 (en) 2025-01-30
WO2024197318A2 (en) 2024-09-26
CN121175070A (zh) 2025-12-19

Similar Documents

Publication Publication Date Title
US20250352652A1 (en) Compounds and methods for the treatment and prevention of fibrotic disease states and cancer
EP3906065B1 (en) Prr agonist for use in the treatment of cancer
KR20210113262A (ko) 패턴 인식 수용체 작용제의 컨쥬게이트
US20250381283A1 (en) Method for treating solid tumor
CA3125488A1 (en) Induction of sustained local inflammation
EP3906032A1 (en) Sustained local drug levels for innate immune agonists
JP2022546806A (ja) 癌免疫療法
WO2020254617A1 (en) Anti-ctla4 compounds with localized pk properties
IL323210A (he) שילובים ושיטות לשיפור טיפולים במעכבי נקודות ביקורת בטיפול בסרטן
US20250269036A1 (en) Methods for enhancement of engineered cell therapies in cancer treatment
WO2020254607A1 (en) Anti-ctla4 compounds with localized pd properties
AU2017265263B2 (en) A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases
RU2817710C2 (ru) Устойчивые локальные уровни лекарственного средства для агонистов врожденного иммунитета
WO2022054625A1 (ja) 核移行性が改良されたピロール－イミダゾールポリアミド
WO2022223544A1 (en) COMBINATION THERAPY OF NUCANT AND mTOR INHIBITORS FOR TREATING CANCER
JP2022527296A (ja) 卵巣の悪性ラブドイド腫瘍および卵巣高カルシウム血症型小細胞がんを処置する方法
JP2018052930A (ja) 新規アルキル化剤